{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "ND5",
        "Protein_Change": {
          "ref": "T",
          "alt": "A",
          "position": "21"
        },
        "variant_string_id": "ND5 T21A"
      },
      "steps": [
        {
          "step": "1. Define the disease mechanism",
          "details": "The study links mitochondrial complex I dysfunction (ND5/ND6 mutations) to increased oxidative stress, a known mechanism in Parkinson's disease (PD). The enhanced superoxide production and altered enzyme kinetics directly implicate these mutations in PD pathogenesis."
        },
        {
          "step": "2. Evaluate assay applicability",
          "details": "The enzyme kinetic analysis and superoxide production assays are directly relevant to complex I dysfunction, which is central to PD pathogenesis. The use of a complex I inhibitor to abrogate the effect validates the assay's relevance."
        },
        {
          "step": "3. Validate specific assays",
          "details": "The study does not explicitly mention controls (e.g., wild-type fibroblasts or known pathogenic variants). However, the use of an inhibitor as a functional control suggests some validation. Standard mitochondrial assays are considered accepted methods."
        },
        {
          "step": "4. Apply evidence to variant interpretation",
          "details": "No explicit OddsPath calculations or statistical thresholds (e.g., p-values, confidence intervals) are reported. The study relies on qualitative functional changes (enhanced superoxide, altered enzyme kinetics) without quantitative statistical analysis."
        }
      ],
      "evidence_strength": "PS3_supporting",
      "functional_evidence_aim": "pathogenic"
    },
    {
      "variant_id": {
        "Gene": "ND6",
        "Protein_Change": {
          "ref": "N",
          "alt": "D",
          "position": "119"
        },
        "variant_string_id": "ND6 N119D"
      },
      "steps": [
        {
          "step": "1. Define the disease mechanism",
          "details": "The study links mitochondrial complex I dysfunction (ND5/ND6 mutations) to increased oxidative stress, a known mechanism in Parkinson's disease (PD). The enhanced superoxide production and altered enzyme kinetics directly implicate these mutations in PD pathogenesis."
        },
        {
          "step": "2. Evaluate assay applicability",
          "details": "The enzyme kinetic analysis and superoxide production assays are directly relevant to complex I dysfunction, which is central to PD pathogenesis. The use of a complex I inhibitor to abrogate the effect validates the assay's relevance."
        },
        {
          "step": "3. Validate specific assays",
          "details": "The study does not explicitly mention controls (e.g., wild-type fibroblasts or known pathogenic variants). However, the use of an inhibitor as a functional control suggests some validation. Standard mitochondrial assays are considered accepted methods."
        },
        {
          "step": "4. Apply evidence to variant interpretation",
          "details": "No explicit OddsPath calculations or statistical thresholds (e.g., p-values, confidence intervals) are reported. The study relies on qualitative functional changes (enhanced superoxide, altered enzyme kinetics) without quantitative statistical analysis."
        }
      ],
      "evidence_strength": "PS3_supporting",
      "functional_evidence_aim": "pathogenic"
    }
  ]
}